Nasdaq Grants Scienture 180-Day Extension to Regain Bid Price Compliance
Summary
Scienture Holdings, a micro-cap pharmaceutical company, has been granted an additional 180-day extension by Nasdaq to regain compliance with the minimum $1.00 bid price requirement, extending the deadline to October 12, 2026. This development provides a crucial reprieve, as the company's recent 10-K filing already disclosed a Nasdaq minimum bid price deficiency and a going concern warning. While the extension prevents immediate delisting, a significant risk for a company of this size, it does not resolve the underlying issue of the low stock price. The company indicated it intends to cure the deficiency, potentially through a reverse stock split. Traders will closely watch for any corporate actions to meet the compliance requirements and the performance of its recently launched and upcoming products, Arbli™ and REZENOPY™, which management hopes will drive revenue growth.
At the time of this announcement, SCNX was trading at $0.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.7M. The 52-week trading range was $0.24 to $2.60. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.